Apellis Pharmaceuticals (APLS) Other Operating Expenses (2020 - 2025)
Apellis Pharmaceuticals has reported Other Operating Expenses over the past 6 years, most recently at $29.7 million for Q4 2025.
- Quarterly results put Other Operating Expenses at $29.7 million for Q4 2025, down 27.26% from a year ago — trailing twelve months through Dec 2025 was $102.2 million (down 13.15% YoY), and the annual figure for FY2025 was $102.2 million, down 13.16%.
- Other Operating Expenses for Q4 2025 was $29.7 million at Apellis Pharmaceuticals, up from $24.5 million in the prior quarter.
- Over the last five years, Other Operating Expenses for APLS hit a ceiling of $50.0 million in Q2 2021 and a floor of $82000.0 in Q2 2022.
- Median Other Operating Expenses over the past 5 years was $20.2 million (2024), compared with a mean of $19.2 million.
- Biggest five-year swings in Other Operating Expenses: crashed 99.84% in 2022 and later surged 10118.29% in 2023.
- Apellis Pharmaceuticals' Other Operating Expenses stood at $30.1 million in 2021, then tumbled by 90.27% to $2.9 million in 2022, then soared by 580.75% to $19.9 million in 2023, then surged by 105.18% to $40.9 million in 2024, then fell by 27.26% to $29.7 million in 2025.
- The last three reported values for Other Operating Expenses were $29.7 million (Q4 2025), $24.5 million (Q3 2025), and $13.6 million (Q2 2025) per Business Quant data.